Thus, drugs that mimic the action of GLP-1, known generally as GLP-1 receptor agonists, are widely used in the management of T2D and obesity, which as outlined above are both closely linked to CKD. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.